Skip to main content
Premium Trial:

Request an Annual Quote

But, Again, Maybe Not

An advisory panel to the US Food and Drug Administration has determined there isn't enough data to gauge whether an Alzheimer's disease drug under investigation works, NPR reports.

Biogen had shelved its aducanumab treatment targeting the accumulation of amyloid protein in the brains of individuals with Alzheimer's disease, but, as Time magazine reported last year, the company later resurrected the drug after a re-analysis of its data suggested that it might have an effect on cognitive decline after all. A recent review of the data by the FDA indicated that the agency might be in agreement with Biogen's finding that patients might benefit from treatment with aducanumab, as Stat News reported last week.

But the advisory panel that met Friday was less sure, according to NPR. It notes that one aducanumab study suggested it worked and another study indicated it did not, but that the FDA asked the panel to focus on the positive one. This, it adds, did not seem to go over well with the panel, which rejected the idea of approving the drug. FDA generally follows the recommendations of its advisory panels.

"Alzheimer's treatment is a huge, urgent, unmet need, but I also think if we approve something where the data is not strong, we have a risk of delaying good treatment," Joel Perlmutter from Washington University in St. Louis, one of the panel members, tells Science.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.